scholarly article | Q13442814 |
P50 | author | Michael A Nardi | Q56246776 |
P2093 | author name string | Jeffrey S Berger | |
Vanessa Valdes | |||
Lindsay Elbaum | |||
P2860 | cites work | Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma | Q57313116 |
CD40-CD40L and platelet function: beyond hemostasis | Q73400879 | ||
Pre-analytical variation in the measurements of sensitive markers of coagulation and fibrinolysis: the influence of venipuncture and mixing of blood | Q73718391 | ||
Platelet P-selectin facilitates atherosclerotic lesion development | Q78654773 | ||
Influence of pre-analytical and analytical factors on soluble CD40L measurements | Q79952846 | ||
P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis | Q28237380 | ||
Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk | Q33362119 | ||
Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data | Q33896059 | ||
Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. | Q35738647 | ||
CD40/CD40L system and vascular disease. | Q37017170 | ||
Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. | Q37127450 | ||
Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. | Q37257153 | ||
The CD40/CD40 ligand system: linking inflammation with atherothrombosis | Q37579360 | ||
Soluble CD40L and cardiovascular risk in women | Q40677583 | ||
Soluble P-selectin and the risk of future cardiovascular events | Q40729226 | ||
Hypothesis: is soluble P-selectin a new marker of platelet activation? | Q41364350 | ||
Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions | Q43198801 | ||
Soluble P-selectin as a marker of in vivo platelet activation | Q46331584 | ||
Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease | Q46794553 | ||
P433 | issue | 1 | |
P921 | main subject | aspirin | Q18216 |
reproducibility | Q1425625 | ||
P304 | page(s) | 83-87 | |
P577 | publication date | 2015-07-01 | |
P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
P1476 | title | Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand | |
P478 | volume | 40 |
Q58577562 | Association between P-selectin levels and left atrial blood stasis in patients with nonvalvular atrial fibrillation |
Q41096059 | Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study |
Q37018644 | Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis |
Q100523696 | Proteomic Profiling Identifies Key Differences Between Inter-Stage Infants with Single Ventricle Heart Disease and Healthy Controls |
Q35735264 | Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization |
Q90723624 | The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease |
Q52725381 | The non-haemostatic role of platelets in systemic lupus erythematosus. |